Diagnostic and clinical utility of comprehensive multigene panel testing for patients with neuropathy
Journal of the Peripheral Nervous System · 2024
DOI: 10.1111/jns.12651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Jennifer Roggenbuck und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University Wexner Medical Center, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Genetic Testing, Peripheral Nervous System Diseases, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims Prior to next‐generation sequencing (NGS), the evaluation of a patient with neuropathy typically consisted of screening for acquired causes, followed by clinical genetic testing of PMP22 , MFN2 , GJB1 , and MPZ in patients with a positive family history and symptom onset prior to age 50. In this study, we examined the clinical utility of NGS in a large cohort of patients analyzed in a commercial laboratory.
Methods
A cohort of 6849 adult patients underwent clinician‐ordered peripheral neuropathy multigene panel testing ranging from 66 to 111 genes that included NGS and intragenic deletion/duplication analysis.
Results
A molecular diagnosis was identified for 8.4% of the cohort ( n = 573/6849). Variants in PMP22 , MFN2 , GJB1 , MPZ , and TTR accounted for 73.8% of molecular diagnoses. Results had potential clinical actionability for 398 (69.5%) patients. Our results suggest that 225/573 (39.3%) of molecular diagnoses and 113/398 (28.4%) of clinical interventions would have been missed if the testing approach had been restricted to older guidelines.
Interpretation
Our results highlight the need for expanded genetic testing guidelines that account for the increased number of genes associated with hereditary neuropathy, address the overlap of acquired and hereditary neuropathy, and provide broader access to genetic diagnosis for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Invitae Corporation, San Francisco, California, USA.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pathology, Stanford University, Stanford, California, USA.
ORCID-Profile: Jennifer Roggenbuck, Steven S Scherer
Zitieren
APA
Roggenbuck, J., Morales, A., Ellis, C. A., Dratch, L., Stetler, M., Tan, C. A., Bucknor, B., Hatchell, K. E., Aradhya, S., Esplin, E. D., Ting, Y. L., & Scherer, S. S. (2024). Diagnostic and clinical utility of comprehensive multigene panel testing for patients with neuropathy. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12651
Vancouver
Roggenbuck J, Morales A, Ellis CA, Dratch L, Stetler M, Tan CA, et al. Diagnostic and clinical utility of comprehensive multigene panel testing for patients with neuropathy. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12651
BibTeX
@article{Roggenbuck2024,
author = {Roggenbuck, Jennifer and Morales, Ana and Ellis, Colin A and Dratch, Laynie and Stetler, Molly and Tan, Christopher A and Bucknor, Brianna and Hatchell, Kathryn E and Aradhya, Swaroop and Esplin, Edward D and Ting, Yi-Lee and Scherer, Steven S},
title = {Diagnostic and clinical utility of comprehensive multigene panel testing for patients with neuropathy},
journal = {Journal of the Peripheral Nervous System},
year = {2024},
doi = {10.1111/jns.12651}
}
EUVIMED